Navigation Links
Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
Date:4/5/2011

tes absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. The Company has agreed to file a registration statement covering the resale of the common stock issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See the Company's Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company's expectations, except as required by law.

CHAMPIONS Oncology, Inc.
855 N. Wolfe Street, Suite 619
Baltimore, Maryland 21205 USA. '/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Biotechnology Changes Name to Champions Oncology
2. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
3. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
4. Champions Biotechnology Reports Additions to its Management Team
5. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
6. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
7. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
8. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
9. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
10. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
11. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... Boston, Mass. (PRWEB) July 10, 2014 ... , today announced that Alan Swahn, a former vice ... Terascala’s executive team as vice president of marketing. Terascala’s ... from Dell and NetApp create the highest performance and ... has been appointed to guide Terascala’s channel expansion and ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Thieme's new book, Islands in the Clickstream is ... WTN will be reprinting excerpts from selected chapters of Islands ... week features an excerpt from chapter four, Hacking and the ... of Thieme's writings. , , Hactivism and Soul Power ...
... this summer, we looked at venture capital funding in ... reached about $5 billion in investments in small companies. ... $5.4 billion invested during the fourth quarter of 2003, ... results for the second quarter of 2004 were a ...
... Source: Office of U.S. Rep. Jane Harman (D-Redondo Beach, Calif.) ... Republican? , ,As silly as that question is, it appears ... lamentable wedge issues of the 2004 presidential campaign. Both political ... a back seat to stem cell politics. , ,If you ...
Cached Biology Technology:Islands in the Clickstream: Hactivism and Soul Power 2Islands in the Clickstream: Hactivism and Soul Power 3Islands in the Clickstream: Hactivism and Soul Power 4Midwest life science companies capture 3% of VC investments in Q.2 2Dividing stem cells along partisan lines isnt a good experiment 2Dividing stem cells along partisan lines isnt a good experiment 3
(Date:7/13/2014)... New research raises the prospect of more effective ... muscle occurring in about half of all cancer patients, ... Dana-Farber Cancer Institute. , Many strategies have been tried ... that patients can,t endure potentially life-saving treatments, but none ... July 13 advanced online edition of Nature , ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... of Entiat on Tuesday, July 8, 2014. Despite the ... over 1,000 acres by evening. Three outbuildings were damaged. ... the Washington Department of Natural Resources. The fire ... fire control strategies and tactics. Other cooperators include the ... Resources, (WA DNR), Bureau of Land Management, Chelan County ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... New findings from Van Andel Research Institute (VARI) scientists ... and other stresses in harsh environments to combat global food ... in Nature last year that were named among ... "I think that the work established the methodologies and ...
... women in the US, the association between the consumption of ... diabetes mellitus (late onset diabetes) was studied for 12 years. ... but the regular moderate intake of both caffeinated coffee and ... diabetes significantly. This paper is particularly important ...
... Sebelius at the U.S. Department of Health and Human ... specific challenges to proposed modifications to HIPAA Privacy and ... its membership of 4,000 informatics professionals, detail key issues ... (NPRM) on HIPAA modifications, along with suggestions for models ...
Cached Biology News:New VARI findings next step to growing drought-resistant plants 2AMIA cites concerns about proposed HIPAA modifications 2AMIA cites concerns about proposed HIPAA modifications 3AMIA cites concerns about proposed HIPAA modifications 4
Direct ELISA Assay Diluent - EDTA, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
... agarose gel electrophoresis into an automated, high-throughput ... bufferless, pre-cast system is ideal for analyzing ... and more. Fully automated, robot-compatible, and ready ... system makes your high-throughput screening assignments as ...
...
Biology Products: